LENZ Therapeutics, Inc. (LENZ)
Automate Your Wheel Strategy on LENZ
With Tiblio's Option Bot, you can configure your own wheel strategy including LENZ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LENZ
- Rev/Share 0.0
- Book/Share 6.9756
- PB 4.6634
- Debt/Equity 0.0062
- CurrentRatio 23.0901
- ROIC -0.3077
- MktCap 915595886.0
- FreeCF/Share -1.8921
- PFCF -17.5802
- PE -18.7563
- Debt/Assets 0.0059
- DivYield 0
- ROE -0.2374
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | LENZ | Piper Sandler | -- | Overweight | $38 | $51 | April 14, 2025 |
| Initiation | LENZ | TD Cowen | -- | Buy | -- | $60 | March 18, 2025 |
| Initiation | LENZ | Raymond James | -- | Outperform | -- | $37 | Sept. 27, 2024 |
News
LENZ Therapeutics, Inc. (LENZ) Q1 2025 Earnings Call Transcript
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Neutral
LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Dan Chevallard - Chief Financial Officer Eef Schimmelpennink - President & Chief Executive Officer Shawn Olsson - Chief Commercial Officer Marc Odrich - Chief Medical Officer Conference Call Participants Stacy Ku - TD Cowen Pawan Patel - Bank of America Yigal Nochomovitz - Citi Lachlan Hanbury-Brown - William Blair Denis Reznik - Raymond James Matthew Caufield - H.C. Wainwright Operator Good afternoon, ladies and gentlemen, and welcome to the LENZ Therapeutics First Quarter 2025 Financial Results Conference Call.
Read More
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced an exclusive license and commercialization agreement for Lotus to commercialize LNZ100 for the treatment of presbyopia in the Republic of Korea and certain countries in Southeast Asia.
Read More
LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference
Published: May 06, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in a fireside chat and one-on-one meetings at the BofA Securities 2025 Health Care Conference taking place May 13- 15, 2025 in Las Vegas, NV.
Read More
LENZ Therapeutics, Inc. (LENZ) Q4 2024 Earnings Call Transcript
Published: March 19, 2025 by: Seeking Alpha
Sentiment: Neutral
LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q4 2024 Results Conference Call March 19, 2025 4:30 PM ET Company Participants Dan Chevallard - Chief Financial Officer Eef Schimmelpennink - President & Chief Executive Officer Shawn Olsson - Chief Commercial Officer Marc Odrich - Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Madhu Yennawar - Leerink Partners Joe Catanzaro - Piper Sandler Stacy Ku - TD Cowen Jason Gerberry - Bank of America Lachlan Hanbury-Brown - William Blair Denis Reznik - Raymond James Matthew Caufield - H.C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the LENZ Therapeutics Year …
Read More
LENZ Therapeutics to Participate in Upcoming Investor Conferences
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in the following upcoming investor conferences:
Read More
About LENZ Therapeutics, Inc. (LENZ)
- IPO Date 2024-03-22
- Website https://www.lenz-tx.com
- Industry Biotechnology
- CEO Evert B. Schimmelpennink
- Employees 6